Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation
Ryota Kurimoto(Chiba University), Yuichi Takiguchi(Sanno Medical Center)
Cited by 70
Related Papers
Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site
|Journal of Clinical Oncology|2019|168
Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site
|JAMA Oncology|2020|119
The mechanosensitive ion channel PIEZO1 is expressed in tendons and regulates physical performance
|Science Translational Medicine|2022|76
Pirfenidone may revert the epithelial-to-mesenchymal transition in human lung adenocarcinoma
|Oncology Letters|2017|39